BeiGene, Ltd. (NASDAQ:BGNE) Receives $247.07 Average Price Target from Analysts

Shares of BeiGene, Ltd. (NASDAQ:BGNE) have been assigned an average rating of “Moderate Buy” from the seven ratings firms that are currently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $247.07.

A number of equities analysts have recently weighed in on BGNE shares. JPMorgan Chase & Co. upped their price objective on BeiGene from $200.00 to $235.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 22nd. TD Cowen upped their price target on BeiGene from $254.00 to $260.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. JMP Securities began coverage on shares of BeiGene in a report on Wednesday, September 18th. They issued a “market outperform” rating and a $288.00 target price on the stock. Citigroup upped their target price on shares of BeiGene from $269.00 to $288.00 and gave the stock a “buy” rating in a research report on Thursday, August 8th. Finally, StockNews.com downgraded shares of BeiGene from a “buy” rating to a “hold” rating in a report on Thursday, November 21st.

Insider Buying and Selling at BeiGene

In related news, insider Xiaodong Wang sold 40,468 shares of the business’s stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $190.10, for a total transaction of $7,692,966.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Xiaobin Wu sold 500 shares of the company’s stock in a transaction on Tuesday, September 17th. The shares were sold at an average price of $200.00, for a total value of $100,000.00. Following the completion of the transaction, the chief operating officer now directly owns 4,500 shares in the company, valued at $900,000. This trade represents a 10.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 57,845 shares of company stock worth $11,514,300 over the last ninety days. Company insiders own 7.43% of the company’s stock.

Institutional Trading of BeiGene

A number of large investors have recently modified their holdings of BGNE. XTX Topco Ltd bought a new stake in BeiGene during the third quarter valued at about $1,614,000. Quantinno Capital Management LP purchased a new stake in shares of BeiGene during the third quarter valued at about $295,000. Point72 Asset Management L.P. boosted its holdings in shares of BeiGene by 74.9% in the 3rd quarter. Point72 Asset Management L.P. now owns 667,166 shares of the company’s stock valued at $149,785,000 after buying an additional 285,784 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of BeiGene in the 3rd quarter worth approximately $67,000. Finally, Erste Asset Management GmbH purchased a new position in shares of BeiGene in the 3rd quarter worth approximately $4,478,000. Hedge funds and other institutional investors own 48.55% of the company’s stock.

BeiGene Stock Performance

Shares of BGNE opened at $205.75 on Friday. The business has a 50-day simple moving average of $212.51 and a two-hundred day simple moving average of $185.01. The company has a quick ratio of 1.72, a current ratio of 1.93 and a debt-to-equity ratio of 0.05. BeiGene has a 52 week low of $126.97 and a 52 week high of $248.16. The stock has a market cap of $20.04 billion, a price-to-earnings ratio of -24.97 and a beta of 0.63.

BeiGene (NASDAQ:BGNE) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.11) by ($0.04). BeiGene had a negative return on equity of 25.12% and a negative net margin of 25.94%. The firm had revenue of $1 billion during the quarter, compared to analysts’ expectations of $983.26 million. During the same period last year, the company earned $2.01 earnings per share. The business’s revenue for the quarter was up 28.2% on a year-over-year basis. On average, analysts expect that BeiGene will post -5.38 EPS for the current year.

About BeiGene

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.